BioStock: Alligator brings in new CFO ahead of phase III

As Alligator Bioscience approaches phase III with its lead cancer immunotherapy candidate mitazalimab, increasing its business development activities has been a top priority. With that goal in mind, the company has appointed Johan Giléus as new CFO. BioStock spoke to Johan to learn more about how he will contribute to the team. 

Read the interview with CFO Johan Giléus at biostock.se:

https://www.biostock.se/en/2024/09/alligator-brings-in-new-cfo-ahead-of-phase-iii

This is a press release from BioStock - Connecting Innovation and Capital.